Clinical trials: Asthma Patients
Asthma (Diagnosis)
Beclometasone Dipropionate and Formoterol Inhalation Aerosol for Asthma
A multicenter, randomized, double-blind, active-controlled, parallel-group Phase III clinical study comparing the efficacy and safety of Beclometasone Dipropionate and Formoterol Inhalation Aerosol versus FOSTER® in patients with…
- Trial name
- NCT07768891
- Testing
- Beclometasone Dipropionate and Formoterol Inhalation Aerosol, FOSTER®
- Where
- China
- Volunteers
- 416 people
- Sponsor
- Lunan Better Pharmaceutical Co., LTD.
Moderate-to-severe Allergic Asthma
A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma
This study will assess the effect of omalizumab on exercise capacity, physical activity, and sleep quality after 24 weeks of treatment in participants with moderate to severe allergic asthma.
- Trial name
- EDURO (NCT04195958)
- Testing
- Omalizumab
- Where
- 12 sites in United States
- Volunteers
- 3 people
- Sponsor
- Genentech, Inc.
Persistent Asthma
Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma
The primary objective of this study is to evaluate the efficacy of beclomethasone dipropionate administered via BAI at a dose strength of 40 or 80 mcg per oral inhalation (320 or 640 mcg/day, respectively) compared with placebo…
- Trial name
- NCT02513160
- Testing
- Beclomethasone Dipropionate 640, Beclomethasone dipropionate via 320 mcg BAI, albuterol/salbutamol
- Where
- 75 sites in United States
- Volunteers
- 713 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Uncontrolled Asthma
Impact of GDMT in Uncontrolled Asthma Patients Receiving MHD Inhaled Corticosteroids + Long-acting β2 Agonist
The primary objective of this study is to evaluate whether GDMT can bring significant benefits to disease management in uncontrolled asthma patients receiving medium- to high-dose ICS-LABA.
- Trial name
- PRECISION (NCT07718724)
- Testing
- Intervention group
- Where
- 20 sites in China
- Volunteers
- 540 people
- Sponsor
- AstraZeneca
To Evaluate
An Evaluation of Exercise Tolerance in Asthmatic Patients
To evaluate exercise tolerance.
- Trial name
- NCT01246154
- Testing
- EXERCISE TRAINING
- Where
- India
- Volunteers
- 15 people
- Sponsor
- Physio Care
Asthma, COPD
Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway
This is a retrospective, multicentre, non-interventional, observational study in patients with asthma and/or COPD who are treated with budesonide-formoterol.
- Trial name
- BufoSwitch (NCT04663386)
- Testing
- Budesonide-Formoterol
- Where
- Norway
- Volunteers
- 29 people
- Sponsor
- Orion Corporation, Orion Pharma
Asthma
Efficacy of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010/M1-137)
The aim of the study is to investigate the efficacy of ciclesonide versus budesonide on lung function, symptoms and use of rescue medication in patients with asthma.
- Trial name
- NCT00163397
- Testing
- Ciclesonide
- Where
- 6 sites in Malaysia, Taiwan
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Asthma
Effect of a Pharmaceutical Intervention on the Level of Control of the Asthmatic Patient
Measurement of disease control, treatment adherence and patient knowledge of his/her medication in patients that are receiving a pharmaceutical intervention compared with those patients who receive regular pharmaceutical care.
- Trial name
- NCT01085474
- Testing
- 1, 2
- Where
- 2 sites in Spain
- Volunteers
- 384 people
- Sponsor
- AstraZeneca
Asthma
The Comparison of Electronic Auscultation Coupled With CALSA and FRI; Repeatability of FRI Biomarkers
CALSA will be compared with FRI and the repeatability of the FRI parameters will be tested in a group of healthy volunteers and asthma patients.
- Trial name
- NCT02228018
- Testing
- CT-scan
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- FLUIDDA nv
Asthma
Investigation of Intravenous (IV) Administration of an Approved Drug (MK-0476, Montelukast Sodium) for Acute Asthma (MK-0476-288)
The purpose of this study is to evaluate improved results of treatment for patients entering an emergency department with asthma attacks when given an investigational IV administration of an approved drug (MK-0476, montelukast…
- Trial name
- NCT00092989
- Testing
- montelukast sodium
- Volunteers
- 650 people
- Sponsor
- Organon and Co
Asthma
Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma
This study will assess the change in the expression of FcεRI receptors of blood basophils and dendritic cells after 16 weeks of treatment with omalizumab as compared with placebo, in adult patients with non-atopic severe…
- Trial name
- NATAIR (NCT01007149)
- Testing
- omalizumab
- Where
- 10 sites in France
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Asthma, Asthma in Children
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
This is a multi-center study to evaluate fractional exhaled nitric oxide (FeNO) measured with the Vivatmo pro in adult and pediatric subjects.
- Trial name
- NCT04450108
- Testing
- Vivatmo pro FeNO Test
- Where
- 6 sites in United States
- Volunteers
- 122 people
- Sponsor
- Bosch Healthcare Solutions GmbH
Asthma
Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma
This study was designed to assess the safety of indacaterol (300 µg and 600 µg (2 x 300 μg capsules) once daily [od]), compared with salmeterol (50 μg twice a day [b.i.d.]), over 26 weeks, in patients with moderate to severe…
- Trial name
- NCT00529529
- Testing
- Indacaterol 300 μg, Salmeterol 50 μg
- Where
- 126 sites in United States, Argentina and 10 more
- Volunteers
- 805 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study in Patients With Asthma
The purpose of this study is to determine which dose of the investigational drug is safest and most effective compared to the control group.
- Trial name
- NCT00215371
- Testing
- Formoterol Fumarate
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dey
Asthma
Assessment of PFT, Safety, and PK of Zileuton Injection in Asthma Patients
A single intravenous injection of zileuton (150 or 300 mg) will be administered to patients with stable asthma. The goals will be to determine if zileuton i.v.
- Trial name
- NCT00534625
- Testing
- zileuton
- Volunteers
- 36 people
- Sponsor
- Critical Therapeutics
Patients With Asthma-COPD Overlap Syndrome (ACOS)
Non-interventional Study of COPD Patients With Asthma Overlap Syndrome in Viet Nam and Taiwan
The purpose of this study to determine the proportion and clinical characteristics of COPD patients with asthma symptoms (ACOS) and describe current practices in diagnosis and management in Viet Nam and Taiwan.
- Trial name
- NCT02878252
- Where
- 5 sites in Taiwan, Vietnam
- Volunteers
- 350 people
- Sponsor
- AstraZeneca
Severe Asthma
Characterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B)
A retrospective, observational, one arm, single country study, using the computerized database of Maccabi Health Services (MHS).
- Trial name
- SAIL-B (NCT07218172)
- Where
- Israel
- Volunteers
- 197 people
- Sponsor
- AstraZeneca
Asthma
Efficacy and Safety of Roflumilast Taken in the Morning or Evening in Patients With Stable Asthma (12 to 70 y) (BY217/M2-015)
Bronchial asthma is among the world's most prevalent diseases. Roflumilast is a novel, orally active, selective enzyme inhibitor (phosphodiesterase 4 inhibitor), which has shown effectiveness in the treatment of asthma.
- Trial name
- NCT00163475
- Testing
- Roflumilast
- Where
- 5 sites in Australia, Belgium and 3 more
- Volunteers
- 511 people
- Sponsor
- AstraZeneca
Severe Asthma
Observational Retrospective Study To Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab in the Framework Of Use in Special Situations Prior to Commercialisation in Spain
The aim of this study is to provide the first results on the use of tezepelumab under clinical practice conditions in severe asthma patients who participated in the "foreign medication supply" program in Spain.
- Trial name
- T-ROSS (NCT06487065)
- Where
- 14 sites in Spain
- Volunteers
- 33 people
- Sponsor
- AstraZeneca
Asthma
GSK2190915 Neutrophilic Asthma Study
The purpose of this study is to investigate the effect on repeat doses of GSK2190915 in asthmatic patients with a high percentage of neutrophils in their sputum.
- Trial name
- NCT01471665
- Testing
- GSK2190915 100mg
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- GlaxoSmithKline